Waljit_Dhillo

Waljit Dhillo

Waljit Dhillo FRCP FMedSci is an endocrinologist and a Professor of Endocrinology & Metabolism at the Imperial College London.[1] He is the Director of Research at the Division of Medicine & Integrated Care at Imperial College Healthcare NHS Trust and the Dean of the National Institute for Health and Care Research (NIHR) Academy.[1][2][3] His research focuses on how the endocrine system controls body weight and reproductive functions.[4]

Quick Facts Fields, Institutions ...

Early life and education

Dhillo studied at the St Bartholomew's Hospital Medical College, University of London. He received a BSc in biochemistry in 1991 and an MBBS in Clinical Pharmacology & Therapeutics in 1994. He acquired a PhD in neuroendocrinology at the Imperial College in 2002.[5]

Career and research

Dhillo works at the Imperial College London, the Imperial College Healthcare NHS Trust and the National Institute for Health and Care Research (NIHR).[1] Since 2023 he is the Scientific Director for Research Capacity and Capabilities at the NIHR Board.[6] In 2024 he was appointed the NIHR Scientific Director for Research Capacity and Capabilities.[7]

He is a Fellow of the Higher Education Academy (FHEA), the Royal College of Physicians (FRCP), and the Royal College of Pathologists (FRCPath).[5] He was awarded an NIHR Research Professorship in 2015[8] and appointed Senior Investigator in 2021.[9] In 2024 he was elected as a Fellow of the Academy of Medical Sciences.[10]

Dhillo's research focuses on how gut hormones regulate the feeling of hunger and the consequent amount of food intake. His research investigates the possible use of gut hormones as medicine that, when administered, would suppress appetite with less side effects than other drugs.[1][11] More recently he researched the use of kisspeptin treatment for infertile women undergoing in vitro fertilization,[12][13] and the role of neurokinin B in the hot flush symptoms of menopausal women.[14][15] His research paved the way for the development of fezolinetant, a drug for the treatment of hot flushes in menopause.[16] He also takes part in the development of the drug MVT-602, a potential treatment for reproductive problems in women.[17]


References

  1. "Home - Professor Waljit Dhillo". www.imperial.ac.uk. Retrieved 2022-02-10.
  2. "Professor Waljit Dhillo named as new dean of NIHR Academy". Healthcare Leader. 2021-04-29. Retrieved 2022-02-10.
  3. Legro, Richard S. (March 2019). "Waljit S. Dhillo, MD". Seminars in Reproductive Medicine. 37 (2): 043–044. doi:10.1055/s-0039-3400463. ISSN 1526-8004. PMID 31847022. S2CID 209407521.
  4. "Professor Waljit Dhillo". www.imperial.nhs.uk. Retrieved 2022-02-10.
  5. "Four Scientific Directors to join new NIHR Board". National Institute for Health and Care Research. Retrieved 2024-01-31.
  6. "Four Scientific Directors to join new NIHR Board". National Institute for Health and Care Research (NIHR). Retrieved 2024-05-28.
  7. "Current NIHR Research Professors". NIHR. Retrieved 2022-02-11.
  8. "Academy of Medical Sciences announces new Fellows for 2024". Academy of Medical Sciences. Retrieved 2024-05-28.
  9. "Hormone 'to restart reproduction'". 2009-03-17. Retrieved 2022-02-10.
  10. "IVF: First baby born using 'safer' method". BBC News. 2013-06-18. Retrieved 2022-02-10.
  11. Devlin, Hannah (2023-05-20). "Drug for hot flushes will transform menopause treatment, doctors say". The Guardian. ISSN 0261-3077. Retrieved 2023-08-23.
  12. Gregory, Andrew (2023-12-18). "'Gamechanging' drug to prevent hot flushes wins approval in UK". The Guardian. ISSN 0261-3077. Retrieved 2024-01-31.

Share this article:

This article uses material from the Wikipedia article Waljit_Dhillo, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.